Increase efficiencies and productivity by automating core reporting tasks for medical writing.
Automate core regulatory report documents across the CTD pyramid and dramatically accelerate submission timelines.
Yseop recognized by TIME for transforming how life sciences teams create regulatory documents with AI automation.
TIME Names Yseop Copilot One of the Best Inventions of 2025 Read More »
A Whitepaper That Looks at How GenAI-Powered Automation Is Helping Teams Prepare for the Future of Regulatory Submissions
Whitepaper: Modernizing CMC Submissions Read More »
Claret Capital Partners has invested €10M in Yseop to support global expansion and accelerate development of its Generative AI platform. Yseop Copilot helps leading pharma companies like Eli Lilly and Novartis create compliant regulatory documentation faster and with greater consistency.
Yseop’s first CMC-focused offering automates the Quality Overall Summary (Module 2.3), a central component of regulatory submissions that pulls structured insights from Module 3.2.
Yseop Expands into CMC: Redefining Regulatory Automation Beyond Clinical Read More »
The FDA has begun using generative AI to review drug submissions, signaling a major shift in regulatory review. Learn how this impacts pharma teams and what it takes to make your content AI-ready.
See how the world’s largest pharmaceutical firms have accelerated drug development and reduced time to market using AI in latest whitepaper.
Whitepaper: Harness the Power of Generative AI in Pharma Read More »
Cognizant’s AI and industry expertise, combined with Yseop’s generative AI platform, aims to improve the productivity of scientific writers across the life sciences value chain
Already a leading provider of Generative AI for life sciences, Yseop leverages AWS for greater scalability and the acceleration of new drug introductions
See how Yseop Copilot is different from other Generative AI technologies across BioPharma and regulated industries.
Yseop Copilot vs. Alternative GenAI Technologies Read More »
Reinforcing Yseop’s unique footprint in the GenAI space for BioPharma, a new investment enables Yseop to expand the scope of its Generative AI offerings and accelerate its leadership position in life sciences.
The Promise And Challenge Of Deploying AI In Clinical Trials Read More »